Allow women access to Mounjaro for PMOS (formally known as PCOS) NHS treatment
The Issue
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a condition affecting approximately 10% of women in their reproductive years. It's a complex hormonal disorder that can lead to serious physical and emotional challenges such as: weight gain, inability to lose weight, irregular menstrual cycles, hirsutism, fertility struggles, increased risk for type 2 diabetes, ovarian cancer, endometrial cancer and heart disease. Despite these profound effects, the primary treatment options currently available—hormonal pills and intrauterine coils—often only act as temporary solutions that merely mask the symptoms rather than tackling the underlying causes of this condition effectively.
Recent studies have shown promising results for the use of Mounjaro, a medication traditionally prescribed for diabetes management, in alleviating the symptoms of PMOS.
Mounjaro works by regulating insulin levels, which in turn can help in balancing other hormones that are typically imbalanced in PMOS. By addressing the root cause—insulin resistance—Mounjaro offers a potential pathway to genuine relief and improvement in the lives of those struggling with PMOS.
Unfortunately, Mounjaro is not widely accessible to women suffering from PMOS in the NHS because of its current classification as a diabetes medication. This oversight is denying many the opportunity to benefit from a treatment that could address the condition more effectively than current, standard hormonal therapies.
We are calling on healthcare providers and regulatory bodies to reassess the accessibility of Mounjaro for women with PMOS, recognizing its potential benefits beyond diabetes management. By enabling broader access to Mounjaro, you can empower millions of women to take control of their health and reduce the long-term complications associated with PMOS.
Join us in urging decision-makers to acknowledge the versatile applications of Mounjaro in treating PCOS. Sign this petition to support women in gaining comprehensive and effective treatment options for their condition. Together, let's advocate for changes that prioritise women's health and well-being over temporary fixes.
Not only this, a pathway needs to be created in order to help women feel “normal” and heard again.
1
The Issue
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a condition affecting approximately 10% of women in their reproductive years. It's a complex hormonal disorder that can lead to serious physical and emotional challenges such as: weight gain, inability to lose weight, irregular menstrual cycles, hirsutism, fertility struggles, increased risk for type 2 diabetes, ovarian cancer, endometrial cancer and heart disease. Despite these profound effects, the primary treatment options currently available—hormonal pills and intrauterine coils—often only act as temporary solutions that merely mask the symptoms rather than tackling the underlying causes of this condition effectively.
Recent studies have shown promising results for the use of Mounjaro, a medication traditionally prescribed for diabetes management, in alleviating the symptoms of PMOS.
Mounjaro works by regulating insulin levels, which in turn can help in balancing other hormones that are typically imbalanced in PMOS. By addressing the root cause—insulin resistance—Mounjaro offers a potential pathway to genuine relief and improvement in the lives of those struggling with PMOS.
Unfortunately, Mounjaro is not widely accessible to women suffering from PMOS in the NHS because of its current classification as a diabetes medication. This oversight is denying many the opportunity to benefit from a treatment that could address the condition more effectively than current, standard hormonal therapies.
We are calling on healthcare providers and regulatory bodies to reassess the accessibility of Mounjaro for women with PMOS, recognizing its potential benefits beyond diabetes management. By enabling broader access to Mounjaro, you can empower millions of women to take control of their health and reduce the long-term complications associated with PMOS.
Join us in urging decision-makers to acknowledge the versatile applications of Mounjaro in treating PCOS. Sign this petition to support women in gaining comprehensive and effective treatment options for their condition. Together, let's advocate for changes that prioritise women's health and well-being over temporary fixes.
Not only this, a pathway needs to be created in order to help women feel “normal” and heard again.
Petition Updates
Share this petition
Petition created on 12 February 2026